IDYAbenzinga

Ideaya Biosciences Announced A Successful FDA Type D Meeting On The Phase 3 Registrational Trial For Darovasertib For Potential Regulatory Approval As Neoadjuvant Therapy For Primary Uveal Melanoma, The Phase 3 Randomized Trial Is Expected To Start In 1H

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on April 14, 2025 by benzinga